Clinical Trial: Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes

U.S., Aug. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07772960) titled 'Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes' on Aug. 13.

Brief Summary: This study will examine two doses of 1.0 mg and 2.0 mg of Semaglutide versus placebo in patients with Alcohol Use Disorder (AUD) and Obesity (Ob) to assess if these doses improve alcohol craving, stress and alcohol use outcomes.

Study Start Date: Oct. 01

Study Type: INTERVENTIONAL

Condition: Alcohol Use Disorder (AUD) Obesity (BMI Equal to or >30)

Intervention: OTHER: Placebo

Placebo - administered one weekly for 20 weeks

DRUG: Semaglutide 1.0 mg

Semaglutide 1.0 mg low dose

DRUG: Semaglutide 2.0 mg

Semagl...